Individualized therapy with azathioprine or 6-mercaptopourine by monitoring thiopurine methyl-transferase (TPMT) activity;Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorización de la actividad de la tiopurina metiltransferasa (TPMT)

Revista Clinica Espanola

Volumn 202, Issue 10, 2002, Pages 555-562

  Gisbert, J P ^a   Gomollon F ^b   Mate J ^a   Pajares, J M ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; FUROSEMIDE; GLUTATHIONE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; OLSALAZINE; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; XANTHINE OXIDASE;

AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; CROHN DISEASE; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0036801121     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(02)71143-0     Document Type: Review

References (83)

1. Tidd DM, Paterson AR. A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 1974;34:738-46.
2. García Sánchez A, Escudero Roldán M, Pérez Calle JL, González Lara V. Utilización en el aío 2000 de la azatioprina y 6-mercaptopurina en el manejo de la enfermedad inflamatoria intestinal. En: González Lara V, editor. Tratamiento médico en el aío 2000. Enfermedad inflamatoria intestinal; p. 113-40.
3. Decaux G, Prospert F, Horsmans Y, Desager JP. Relationship between red cell mean corpuscular volume and 6-thioguanine nucleotides in patients treated with azathioprine. J Lab Clin Med 2000; 135:25662.
4. Colonna T, Korelitz BI. The role of leukopenia, in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
5. Belaiche J, Desager JP, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease. Scand J Gastroenterol 2001;36:71-6.
6. Dubinsky MC, Lamothe 5, Yang HY, et al. Pharrnacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-13.
7. Markowitz J, Grancher K, Mandel F, Daum F. Relationship of leukopenia to 6-MP induced remission of Crohn's disease. J Pediatr Gastroenterol Nutr 1998;27:A8.
8. Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999;117:527-35.
9. Lennard L, Brown CB, Fox M, Maddocks JL. Azathioprine metabolism in kidney transplant recipients. Br J Clin Pharmacol 1984;18:693-700.
10. Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987;423169-78.
11. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-23.
12. Cuffari C, Theoret Y, Latour S, Seidman G. 6-mercaptopurine metabolism in Crohn's disease; correlation with efficacy and toxicity. Gut 1996;39:401-6.
13. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathloprine therapy in patients with inflammatory bowel disease. Gut 2001;48:642-6.
14. Lilleyman JS, Lennard L. Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 1994;343:1188-90.
15. Bergan S, Rugstad HE, Bentdal O, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes afier renal transplantation. Transplantation 1998;66:334-9.
16. Schutz E, Gummert J, Armstrong VW, Mohr FW, Oellerich M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur J Clin Chem Clin Biochem 1996;34:199-205.
17. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism, Clin Pharmacol Ther 1989;46:149-54.
18. Sandbom WJ, Faubion WA. Clinical pharmacology of inflammatory bowel disease therapies. Curr Gastroenterol Rep 2000;2:440-5.
19. Cuffari C, Picco M, Hunt S, Bayless T. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD. Gastroenterology 1999;116:A694.
20. Dubinsky MC, Lamothe S, Yang HY, et al. Optimizing and individualizing 6-MP therapy in IBD: the role of 6-MP metabolite levels and TPMT genotyping, Gastroenterology 1999;116;A702.
21. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
22. Lowry PW, Franklin CL, Weaver AL. Cross-sectional study of IBD patients taking azathioprine (AZA) or 6-mercaptopurine (6-MP): lack of correlation between disease activity and 6-thioguanine nucleotide (6-TGN) concentration. Gastroenterology 2000;118:A788.
23. Gupta R Gokhale R, Kirsher B, 6-mercaptopurine (6MP) metabolite levels in children with IBD: lack of correlation of 6-thioguanine (6TG) levels with clinical response. Gastroenterology 2000; 118:4202.
24. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;149:665-70.
25. Dubinsky MC, Hassard PV, Abreu MT Thioguanine (6-TG): a therapeutic alternative in a subgroup of IBD patients failing 6-mercaptopurine (6-MP). Gastroenterology 2000:A891.
26. Vesell ES. Therapeutic lessons from pharmacogenetics. Ann Intern Med 1997;126:653-5.
27. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988;47:503-5.
28. Bacon BR, Treuhaft WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Mcd 1981;141:223-6.
29. Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism. Ther Drug Monit 1996;18;328-34.
30. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic poymorphism: a review. J R Soc Med 1992;85:752-6.
31. Bergan S, Rugstad HE, Klemetsdal B, et al. Possibilities for therapeutic drug monitoring of azathioprine: 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther Drug Monit 1997;19:318-26.
32. Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol 1999; 47:131-43.
33. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62.
34. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
35. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol 2001;19:2293-301.
36. Krvnetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res 1999;16:342-9.
37. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
38. Corominas H, Domenech M, González-Juan D, et al. Aplasia medular tras administración de azatioprina: papel del polimorfismo genético de la tiopurina metiltransferasa. Med Clin (Barc) 2000;115:299-301.
39. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8.
40. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.
41. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency; two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996;58:694-702.
42. Ottemess D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997:62;60-73.
43. Spire-Vayron de la Moureyre C, Debuysere H, Sabbagh N, et al. Detection of Imown and new mutations in the thiopurine 5-methyltransferase gene by single-strand conformation polymorphism analysis. Hum Mutat 1998;12:177-85.
44. Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999;8:371-6.
45. Ameyaw MM, Collie-Duguid ES, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999;8:367-70.
46. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B, et al. Genotypic and phenotypic analysis of the polymorphic thiopurine 5-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 1998;125:879-87.
47. Corominas H, Domenech M, González D, et al. Allelic variants of the thiopurine S-methyltransferase deficiency in patients with ulcerative colitis and in healthy controls. Am J Gastroenterol 2000;95:2313-7.
48. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
49. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-33.
50. Jacqz-Aigrain E, Bessa E, Medard Y, Mircheva Y, Vilmer E. Thiopurine methyltransferase activity in a French population; h.p.l.c. assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol 1994;38:1-8
51. Rossi AM, Bianchi M, Guarnien C, Barale R, Pacifici GM. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 2001;57:51-4.
52. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
53. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients. Transplantation 1992;53:1051-6.
54. Pazmino PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980;28:356-67.
55. Lennard L, Van Loon JA, Lilleyman JS, Weinshilbourn RM. Thiopurine pharrnacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41:18-25.
56. McLeod HL, Relling MV, Liu Q, Pul CH, Evans WE. Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995;85:1897-902.
57. Klemetsdal B, Straume B, Wist E, Aarbakke J. Identification of factors regulating thiopurine methyltransferase activity in a Norwegian population. Eur J Clin Pharmacol 1993;44:147-52.
58. Pacifici GM, Romiti P, Giuliani L, Rane A. Thiopurine methyltransferase in humans: development and tissue distribution. Dev Pharmacol Ther 1991:17:16-23.
59. Mircheva J, Legendre C, Soria-Royer C, Thervet E, Beaune P, Kreis H. Monitoring of azathioprine-induced immunosuppression with thiopurine methyltransferase activity in kidney transplant recipients. Transplantation 1995;60:639-42.
60. Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase; possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39;456-9.
61. Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
62. Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001;49:656-64.
63. Lennard L. Clinical implications of thiopurine methyltransferase optimization of drug dosage and potential drug interactions. Ther Drug Monit 1998;20:527-31.
64. Balis FM, Adamson PC. Application of pharmacogenetics to optimization of mercaptopurine dosing. J Natl Cancer Jnst 1999;91:1983-5.
65. Tavadia SM, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000;42:628-32.
66. Schwab M, Schaeffeler W, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only, Gastroenterology 2001;121:500-1.
67. Lorenzen I, Brun C, Videbaek A. Treatment of Immunologic diseases with cytostatics. Acta Med Scand 1969;185: 501-6.
68. Ginzler E, Sharon E, Diamond H. Kaplan D. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum 1975;18:27-34.
69. Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann NY Acad Sci 1981; 377:691-9.
70. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intem Med 1989; 111:641-9.
71. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34;1081-5.
72. Ishioka S, Hiyama K, Sato H, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999;38:944-7.
73. Andersen JB, Szumlanski C, Weinshilboum RM, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 1998;87:108-11.
74. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997;40:1896-8.
75. Gummert JF, Schutz E, Oellerich M, Mohr FW, Dalichau H. Monitoring of TPMT in heart transplant recipients under immunosuppressive therapy with azathioprine. Artif Organs 1995;19:918-20.
76. Ben Ari Z, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23:351-4.
77. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA. Azathloprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:142-5.
78. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology (Oxford) 1999;38:640-4.
79. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1858-66.
80. Sandbom WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001;48:591-2.
81. Evans WE, Homer M, Chu YQ, Kalwinsky D, Roberts WM, Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991;119:985-9.
82. Lennard L, Lewis IJ, Michelagnoli M, Lilleyman JS. Thiopurine methyltransferase deficiency in childhood Lymphoblastic leukemia: 6-mercaptopurine dosage strategies. Med Pediatr Oncol 1997;29;252-5.
83. Kader HA, Wenner WJ Jr., Telega GW, Mailer ES, Baklassano RN. Normal thiopurine methyltransferase levels do not eliminate 6 mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol 2000;30:409-13.